AGN 229666

Drug Profile

AGN 229666

Alternative Names: AGN-229666

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Eye disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic conjunctivitis

Most Recent Events

  • 16 Aug 2017 Senju Pharmaceutical initiates enrolment in a clinical trial for Allergic conjunctivitis (Prevention) in Japan (Ophthalmic) (UMIN000028492)
  • 01 Aug 2017 Senju Pharmaceutical plans a clinical trial for Allergic conjunctivitis (Prevention) in Japan (Ophthalmic) (UMIN000028492)
  • 31 Jan 2017 Senju Pharmaceutical initiates a phase III trial for Allergic conjunctivitis in Japan (Ophthalmic) (UMIN000025876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top